Glucose monitoring products provider Dexcom has signed a development agreement with Eli Lilly to combine their tools for offering better diabetes management to patients.
The firms will integrate Dexcom continuous glucose monitoring (CGM) and Lilly’s smart insulin delivery devices into the Connected Diabetes Ecosystem.
In addition to CGM, Lilly’s Connected Diabetes Ecosystem is set to include devices smart-pens, insulin pumps, drugs, apps and additional analytical tools to minimise complexity and burden for improved patient outcomes.
Dexcom president and CEO Kevin Sayer said: “As technology converges in our industry, we believe that connected systems will become the standard of care over time.
“By combining devices, drugs and technology, we can deliver solutions that adapt to each person’s unique needs in managing their diabetes while also providing compelling advancements for both physicians and payers.”
The firms intend to initiate clinical trials for the Connected Diabetes Ecosystem by the end of this year.
Lilly Diabetes and Lilly USA president Enrique Conterno said: “The Connected Diabetes Ecosystem relies not only on Lilly’s core diabetes expertise but also the strength of our key partners such as Dexcom.
“Dexcom will be an important collaborator in our mission to improve outcomes and reduce the daily burden for people with diabetes.”
The Dexcom G5 CGM system is designed to provide real-time glucose readings every five minutes for type 1 or type 2 diabetes paediatric and adult patients.
The system also allows patients to safely access and share glucose data to a smart device.